ShortCourse
Description

Faculty: Louis P. Garrison, PhD, Professor Emeritus, The Comparative Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA Adrian Towse, MA, MPhil, Director Emeritus and Senior Research Fellow, Office of Health Economics, London, UK; Josh Carlson, MPH, PhD, Associate Professor, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA

It will be helpful for individuals to have completed the ISPOR short course, “Elements of Pharmaceutical / Biotech Pricing ,” or to be familiar with pharmaceutical pricing and the main international health systems.

Level: Intermediate

Track: Health Policy & Regulatory

There is significant and growing interest among both the payers and producers of medical products for arrangements that involve a “pay-for-performance” or “risk-sharing” element. These payment schemes involve a plan by which the performance of the product is tracked in a defined patient population over a specified period of time and the level of reimbursement is tied by formula to the outcomes achieved. Although these agreements have an intrinsic appeal, there can be substantial barriers to their implementation. Issues surrounding theory and practice, including incentives and barriers, will be analyzed along with several examples of performance-based schemes from Europe, the United States, and Australia. A hypothetical case study will be used in an interactive session to illustrate a systematic approach to weighing their applicability and feasibility.
Tags